Compare Stocks: XBIT, ABBV, ABCL, and ABEO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$286.10 -0.1%	$267.66	$190.75 ▼ $291.40	$505.47B	0.24	6.34 million shs	3.11 million shs
ABCL AbCellera Biologics	$13.64 +6.3%	$12.20	$2.74 ▼ $15.02	$4.18B	1.41	5.97 million shs	3.05 million shs
ABEO Abeona Therapeutics	$4.55 +2.2%	$5.34	$4.00 ▼ $7.65	$260.17M	1.31	1.26 million shs	595,424 shs
XBIT XBiotech	$1.99 +7.6%	$2.17	$1.80 ▼ $3.44	$60.68M	0.79	42,165 shs	309,832 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-0.06%	-0.68%	+8.41%	+8.77%	+25.76%
ABCL AbCellera Biologics	+6.21%	+9.56%	+1.02%	+138.03%	+122.36%
ABEO Abeona Therapeutics	+3.25%	-3.26%	-17.59%	-28.57%	-19.68%
XBIT XBiotech	0.00%	-8.42%	-14.75%	-17.78%	-28.02%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$286.10 -0.1%	$267.66	$190.75 ▼ $291.40	$505.47B	0.24	6.34 million shs	3.11 million shs
ABCL AbCellera Biologics	$13.64 +6.3%	$12.20	$2.74 ▼ $15.02	$4.18B	1.41	5.97 million shs	3.05 million shs
ABEO Abeona Therapeutics	$4.55 +2.2%	$5.34	$4.00 ▼ $7.65	$260.17M	1.31	1.26 million shs	595,424 shs
XBIT XBiotech	$1.99 +7.6%	$2.17	$1.80 ▼ $3.44	$60.68M	0.79	42,165 shs	309,832 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-0.06%	-0.68%	+8.41%	+8.77%	+25.76%
ABCL AbCellera Biologics	+6.21%	+9.56%	+1.02%	+138.03%	+122.36%
ABEO Abeona Therapeutics	+3.25%	-3.26%	-17.59%	-28.57%	-19.68%
XBIT XBiotech	0.00%	-8.42%	-14.75%	-17.78%	-28.02%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.83	Moderate Buy	$279.86	-2.18% Downside
ABCL AbCellera Biologics	2.80	Moderate Buy	$13.89	1.82% Upside
ABEO Abeona Therapeutics	2.67	Moderate Buy	$21.00	361.54% Upside
XBIT XBiotech	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest XBIT, ABBV, ABCL, and ABEO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/23/2026	ABBV AbbVie	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$258.00 ➝ $294.00
10/21/2026	ABBV AbbVie	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$300.00 ➝ $325.00
10/16/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/15/2026	ABCL AbCellera Biologics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/13/2026	ABBV AbbVie	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$280.00
10/12/2026	ABCL AbCellera Biologics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$18.00
10/11/2026	ABCL AbCellera Biologics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
10/9/2026	ABBV AbbVie	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$288.00
10/8/2026	ABBV AbbVie	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy (B-) ➝ Buy (B)
10/8/2026	ABBV AbbVie	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$285.00 ➝ $300.00
10/8/2026	ABBV AbbVie	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$285.00 ➝ $290.00

(Data available from 10/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$61.16B	8.26	$15.17 per share	18.86	($1.83) per share	-156.34
ABCL AbCellera Biologics	$75.13M	55.67	N/A	N/A	$3.23 per share	4.22
ABEO Abeona Therapeutics	$5.82M	44.70	N/A	N/A	$2.94 per share	1.55
XBIT XBiotech	N/A	N/A	N/A	N/A	$4.60 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.23B	$3.54	80.82	17.83	1.30	9.80%	-422.07%	14.34%	10/30/2026 (Estimated)
ABCL AbCellera Biologics	-$146.41M	-$0.54	N/A	N/A	N/A	-248.83%	-17.49%	-12.36%	11/9/2026 (Confirmed)
ABEO Abeona Therapeutics	$71.18M	-$1.09	N/A	N/A	N/A	N/A	-41.69%	-30.36%	11/11/2026 (Estimated)
XBIT XBiotech	-$45.54M	-$1.48	N/A	N/A	N/A	N/A	-31.62%	-30.29%	N/A

Latest XBIT, ABBV, ABCL, and ABEO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	ABEO Abeona Therapeutics	-$0.14	N/A	N/A	N/A	$14.82 million	N/A
11/9/2026	Q3 2026	ABCL AbCellera Biologics	-$0.1757	N/A	N/A	N/A	$6.25 million	N/A
10/30/2026	Q3 2026	ABBV AbbVie	$3.73	N/A	N/A	N/A	$17.32 billion	N/A
8/13/2026	Q2 2026	ABEO Abeona Therapeutics	-$0.2317	-$0.35	-$0.1183	-$0.35	$12.24 million	$11.38 million
8/13/2026	Q2 2026	XBIT XBiotech	$0.03	-$0.22	-$0.25	-$0.22	$7.00 million	N/A
8/5/2026	Q2 2026	ABCL AbCellera Biologics	-$0.1640	-$0.18	-$0.0160	-$0.18	$7.85 million	$4.05 million
7/31/2026	Q2 2026	ABBV AbbVie	$3.61	$3.65	+$0.04	$2.03	$16.80 billion	$16.99 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	N/A	N/A	+6.80%	N/A	53 Years
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
XBIT XBiotech	N/A	N/A	N/A	N/A	N/A

Latest XBIT, ABBV, ABCL, and ABEO Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
9/10/2026	ABBV AbbVie	quarterly	$1.73	2.44%	10/15/2026	10/15/2026	11/16/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	N/A	0.81	0.69
ABCL AbCellera Biologics	N/A	12.77	12.77
ABEO Abeona Therapeutics	0.01	6.63	6.40
XBIT XBiotech	N/A	33.15	33.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
ABCL AbCellera Biologics	61.42%
ABEO Abeona Therapeutics	80.56%
XBIT XBiotech	55.70%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.06%
ABCL AbCellera Biologics	28.40%
ABEO Abeona Therapeutics	7.10%
XBIT XBiotech	21.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	57,000	1.77 billion	1.77 billion	Optionable
ABCL AbCellera Biologics	562	306.61 million	219.53 million	Optionable
ABEO Abeona Therapeutics	226	57.18 million	53.12 million	Optionable
XBIT XBiotech	87	30.49 million	24.06 million	Optionable

XBIT, ABBV, ABCL, and ABEO Headlines

Recent News About These Companies

XBiotech (NASDAQ:XBIT) Director John Simard Acquires 368,524 Shares of Company Stock

1 hour ago | marketbeat.com

XBiotech Inc.: XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers

October 23, 2026 | finanznachrichten.de

XBiotech names co-CEOs as Simard joins Shivaswamy in leadership

October 23, 2026 | streetinsider.com

XBiotech Appoints Jan-Paul Simard as Co-Chief Executive Officer Alongside Dr. Sushma Shivaswamy

October 23, 2026 | quiverquant.comQ

XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers

October 23, 2026 | globenewswire.com

XBiotech Inc.: XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer

October 19, 2026 | finanznachrichten.de $https://www.finanznachrichten.de/nachrichten-2026-10/69873296-xbiotech-inc-xbiotech-announces-positive-phase-ii-final-efficacy-results-from-investigator-sponsored-taskin-trial-in-refractory-metastatic-colorecta-399.htm$

XBiotech's TASKIN Trial Meets Primary Efficacy Criterion In Metastatic Colorectal Cancer

October 19, 2026 | rttnews.com

XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer

October 19, 2026 | finance.yahoo.com

XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis

June 15, 2026 | globenewswire.com

XBiotech’s New Axial Spondyloarthritis Trial Puts Vilamakitug on Investors’ Radar

May 14, 2026 | tipranks.com

XBiotech: Q4 Earnings Snapshot

March 13, 2026 | chron.com

XBiotech’s New Trial: A Potential Game-Changer for Rheumatoid Arthritis Treatment?

October 28, 2025 | msn.com

XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 52% stake, while 36% is held by insiders

August 28, 2025 | finance.yahoo.com

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

March 2, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

March 1, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 28, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 27, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 26, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 25, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 24, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 23, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

XBIT, ABBV, ABCL, and ABEO Company Descriptions

AbbVie NYSE:ABBV

$286.10 -0.30 (-0.10%)

Closing price 03:59 PM Eastern

Extended Trading

$287.56 +1.46 (+0.51%)

As of 06:14 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbCellera Biologics NASDAQ:ABCL

$13.64 +0.81 (+6.31%)

Closing price 04:00 PM Eastern

Extended Trading

$13.54 -0.10 (-0.70%)

As of 06:14 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Abeona Therapeutics NASDAQ:ABEO

$4.55 +0.10 (+2.25%)

Closing price 04:00 PM Eastern

Extended Trading

$4.58 +0.03 (+0.75%)

As of 05:55 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

XBiotech NASDAQ:XBIT

$1.99 +0.14 (+7.57%)

Closing price 04:00 PM Eastern

Extended Trading

$1.98 -0.01 (-0.75%)

As of 06:03 PM Eastern

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XBIT, ABBV, ABCL, and ABEO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XBIT, ABBV, ABCL, and ABEO Earnings

Compare Dividends

Latest XBIT, ABBV, ABCL, and ABEO Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XBIT, ABBV, ABCL, and ABEO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

XBIT, ABBV, ABCL, and ABEO Company Descriptions

AbbVie NYSE:ABBV

AbCellera Biologics NASDAQ:ABCL

Abeona Therapeutics NASDAQ:ABEO

XBiotech NASDAQ:XBIT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools